|
Price: $0.3402
$-0.06 
-14.971%
|
| Day's High:
| $0.4102
| Week Perf:
| -39.2 %
|
| Day's Low: |
$ 0.30 |
30 Day Perf: |
-79 % |
| Volume (M): |
543 |
52 Wk High: |
$ 0.00 |
| Volume (M$): |
$ 185 |
52 Wk Avg: |
$0.00 |
| Open: |
$0.40 |
52 Wk Low: |
$0.00 |
|
|
| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
0 |
| Employees |
3,600 |
| Revenues (TTM) (Millions $) |
2,291 |
| Net Income (TTM) (Millions $) |
171 |
| Cash Flow (TTM) (Millions $) |
39 |
| Capital Exp. (TTM) (Millions $) |
26 |
Mallinckrodt Plc
Mallinckrodt Plc is a specialty pharmaceutical company that develops and manufactures a wide range of medical products used in the treatment of rare and critical diseases.
The company was founded in 1867 and is headquartered in Dublin, Ireland, with its primary commercial offices located in the United States. With a rich history of over 150 years, Mallinckrodt has become a leading provider of medical products and services in the healthcare industry, serving millions of patients worldwide.
The company's pharmaceutical products cover a range of areas, including pain management, autoimmune and rare diseases, respiratory disorders, and central nervous system disorders. Mallinckrodt is known for producing specialty drugs such as Acthar Gel, a drug used in the treatment of autoimmune disorders, and Ofirmev, an intravenous acetaminophen injection used for pain management in hospitals.
In addition to pharmaceutical products, Mallinckrodt also produces medical devices and diagnostics tools. The company's medical devices line includes products such as surgical instruments, single-use catheters, and implantable devices for spine and orthopedics. Its diagnostics business offers various imaging agents and injectable dyes used in radiology and cardiology procedures.
Mallinckrodt's operations span over 40 countries, with manufacturing facilities located in the Americas, Europe, and Asia. The company employs over 4,500 people and maintains strong partnerships with healthcare providers and researchers.
Mallinckrodt has a strong commitment to social responsibility and sustainability. The company has implemented green initiatives to reduce its environmental footprint, such as carbon emissions reduction targets, waste diversion programs, and water conservation efforts. Furthermore, the company supports various community outreach programs, including those focused on education, health, and the environment.
Overall, Mallinckrodt is a reputable and innovative pharmaceutical company known for its high-quality products and commitment to improving patient care. Its dedication to social responsibility and sustainability has also garnered the company a positive reputation in the healthcare industry.
Company Address: College Business & Technology Park Dublin 15
Company Phone Number: 696 0000 Stock Exchange / Ticker: MNK
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Mallinckrodt Plc
As a financial analyst for the CSIMarket.com, I have been closely monitoring the recent financial results of Mallinckrodt Plc, a Major Pharmaceutical Preparations company. The company's revenue saw a significant increase of 10.193% from the previous year, reaching $467.00 million in the January to March 29 2024 interval. This growth outpaced its sector peers, who only experienced a 2.49% revenue advance during the same period.
Despite the revenue growth, Mallinckrodt Plc reported a loss of $3.32 per share in the first quarter of 2024. This was a decrease from the earnings per share of $6.70 in the preceding financial reporting period, where revenue tumbled by -42.573% from $813.20 million. It is worth noting that the company's net loss also decreased from $249.300 million to $65.400 million compared to the same period a year ago.
|
| Mallinckrodt Plc
Mallinckrodt Plc Reports Positive Financial Results for Fourth Quarter of 2023
Mallinckrodt Plc has posted impressive financial results for the fourth quarter of 2023, turning a profit after a challenging year. The company reported earnings per share of $6.70, a significant improvement from the negative $0.76 reported in the same period a year before. Moreover, EPS turned positive from a staggering negative $128.60 per share in the previous reporting period.
Despite a slight decrease in revenue by -6.593% to $813.20 million compared to $870.60 million in the previous year, Mallinckrodt Plc saw a significant sequential increase of 63.688% from $496.80 million. The company booked net earnings of $2,004.500 million in the fourth quarter of 2023, a substantial improvement from a net deficit of $-119.400 million in the same period the year before.
|
| Mallinckrodt Plc
Mallinckrodt Plc, a major player in the pharmaceutical industry, recently released its financial results for the third quarter of 2023. The report highlights important figures such as earnings per share, revenue growth, net loss, and inventory levels. This article aims to explain and analyze these figures, comparing them to previous periods and industry peers.
Earnings per Share and Revenue Growth
In Q3 2023, Mallinckrodt Plc experienced a substantial increase in the loss per share compared to the previous year and the previous reporting season. The loss per share rose to $-128.60 from $-21.58 in the same period a year before, and $-56.74 from the previous reporting season.
|
| Mallinckrodt Plc
Mallinckrodt Plc, a major player in the pharmaceutical preparations industry, reported a surge in revenue of 24.027% to $474.90 million in the fiscal time-frame ending June 30, 2023, compared to the previous year. While this increase in revenue may seem positive at first glance, a closer look at the financials reveals concerning trends that suggest the company's prospects may not be as favorable as they appear.
One alarming aspect is the significant increase in the deficit per share, which stands at a staggering $-56.74 per share. This is a sharp rise from the previous period's deficit of $-18.93 per share, indicating a deteriorating financial situation for Mallinckrodt. Furthermore, the company's net deficit for the second quarter of 2023 reached a whopping $-747.800 million, a considerable surge from $-193.500 million in the previous year. These figures raise serious concerns about the company's ability to manage its finances effectively and generate sustainable profits.
|
| Mallinckrodt Plc
As a journalist, I am interpreting the financial results of Mallinckrodt Plc, a major pharmaceutical company. According to the financial report, the company's ability to collect accounts receivable sequentially worsened to 4.68, which is quite low and points towards a challenging and deteriorating business climate for the industry.
The average receivable collection period for the company in the first quarter of 2023 was 78 days, which is longer than the 76 days reported in the previous quarter of September 2022. This increase is not favorable, as it indicates that the company is taking more time to collect payments from clients.
|
| Per Share |
Current |
| Earnings (TTM) |
-127.42 $ |
| Revenues (TTM) |
116294.42 $
|
| Cash Flow (TTM) |
1964.47 $ |
| Cash |
14776.65 $
|
| Book Value |
53223.35 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-127.42 $
|
| Revenues (TTM) |
116294.42 $ |
| Cash Flow (TTM) |
1964.47 $ |
| Cash |
14776.65 $
|
| Book Value |
53223.35 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Specialty Generics |
|
 46.63 % |
of total Revenue |
| Specialty Brands |
|
53.37 % |
of total Revenue |
| Acthar Specialty Brands |
|
22.89 % |
of total Revenue |
| Inomax Specialty Brands |
|
12.91 % |
of total Revenue |
| Therakos immunotherapy Specialty Brands |
|
13.07 % |
of total Revenue |
| Amitiza Specialty Brands |
|
2.97 % |
of total Revenue |
| Other Specialty Brands |
|
0.51 % |
of total Revenue |
| Opioids Specialty Generics |
|
18.51 % |
of total Revenue |
| ADHD Specialty Generics |
|
8.13 % |
of total Revenue |
| Addiction Treatment Specialty Generics |
|
4.08 % |
of total Revenue |
| Other Generics Specialty Generics |
|
0.7 % |
of total Revenue |
| Generics Specialty Generics |
|
31.42 % |
of total Revenue |
| Controlled substances Specialty Generics |
|
5.13 % |
of total Revenue |
| APAP Specialty Generics |
|
9.2 % |
of total Revenue |
| Other API Specialty Generics |
|
0.87 % |
of total Revenue |
| API Specialty Generics |
|
15.21 % |
of total Revenue |
| Terlivaz Specialty Brands |
|
1.03 % |
of total Revenue |
|
|
